Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04814303
Other study ID # Adductor canal block in TKR
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 2021
Est. completion date August 2022

Study information

Verified date March 2021
Source Assiut University
Contact Shimaa A Hassan, M.D.
Phone 01002953253
Email shimaa.abbas@med.aun.edu.eg
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

TKA involves extensive bone resection as well as soft tissue excision and therefore is associated with profound postoperative pain. Adequate analgesia after TKA is therefore considered paramount to facilitate early hospital discharge and effective functional recovery.


Description:

Osteoarthritis (OA) of the knee has become a major public health issue and imposes a significant healthcare burden and accounts for high annual hospitalizations. Chronic OA of the knee may lead to reduced physical fitness, mobility disability with a resultant increased risk of cardio-metabolic comorbidity and early mortality. Total knee arthroplasty (TKA) is indicated in severe cases to improve long-term pain and function. (1) TKA involves extensive bone resection as well as soft tissue excision and therefore is associated with profound postoperative pain. (2) Inadequate perioperative pain control may prolong hospitalization, hinder early rehabilitation, and is also a strong predictor of persistent pain beyond 3 months. (3) Adequate analgesia after TKA is therefore considered paramount to facilitate early hospital discharge and effective functional recovery. (4) The recently introduced adductor canal block (ACB) typically covers the anterio-medial aspect of the knee and preserves quadriceps function, which presumably enhances postoperative rehabilitation by allowing patients to actively participate in knee movement. The relative effectiveness of this ACB technique added to intrathecal morphine is limited to a single study (1) in which assessment of short-term functional recovery was done and dexamethasone was neither included in the LIA solution nor perineurally in the ACB. Thus, we hypothesize that adductor canal block as an adjunct to intrathecal morphine will have a better impact on functional recovery than peri-articular infiltration.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 200
Est. completion date August 2022
Est. primary completion date May 2022
Accepts healthy volunteers No
Gender All
Age group 45 Years to 85 Years
Eligibility Inclusion Criteria: - American Society of Anesthesiologist class ( ASA) I - III - BMI 18-35 kg/m2 - Scheduled for primary unilateral TKR Exclusion Criteria: - Known allergy to local anesthetics - Contraindication to adductor canal block e.g. infection at the site of injection - Contraindication to spinal anesthesia e.g. coagulopathy. - Patients with pre-existing motor or sensory deficits in lower extremities. - Patients who are morbidly obese (BMI=35) because ultrasound-guided regional anesthesia could be technically difficult. - Bilateral or revision total knee replacement - Insulin or noninsulin-dependent diabetes mellitus. - systemic corticosteroid use within 30-days of surgery

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Intrathecal morphine
After applying standard monitoring of pulse oximetry, ECG, NIBP; while the patient in the sitting position following complete sterile aseptic condition after sterilization bovine bethidine spinal anesthesia will be induced with heavy bupivacaine 0.5% 12.5-15 mg (2.5-3 mL) at L3-4 or L4-5 inter-vertebral levels using a 25- gauge Whitacre needle. Intrathecal morphine 150 µg will be added to patients of both groups. Supplemental oxygen will be administered via a simple face mask.
Adductor Canal block
The block will be performed in the mid adductor canal to block both the saphenous and the nerve to vastus medialis. After skin infiltration with 1 to 2 mL of 2% lidocaine, an 80-mm, 22-gauge, short-bevel echogenic needle is advanced in plane with the ultrasound beam in an anterior-to-posterior direction until the tip is located within the adductor canal deep to the vastoadductor membrane. After negative aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection plane. The study solution will be injected within the canal adjacent to the femoral artery. Patients in group 1 received 30 mL of 0.25% bupivacaine with 1:400,000 epinephrine and 4 mg dexamethasone.
Peri-articular Infilteration
the surgeon will perform the PAI intra-operatively; 150 mL of 0.25% bupivacaine with 1:400,000 epinephrine, 30 mg of ketorolac, and 8 mg dexamethasone. Half of the solution will be administered into the posterior capsule and posterior soft tissues of the knee under direct vision after osteotomy but before insertion of the implants. The remaining half of the solution will be administered into the anterior soft tissues after placement of the implants and before skin closure. All local infiltration will be carried out while a thigh tourniquet (used to limit surgical bleeding) was inflated at a pressure of 300 to 350 mm Hg.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Outcome

Type Measure Description Time frame Safety issue
Primary "Timed Up and Go" test (TUG) reflects the time it takes a subject to stand up from a standard-height armchair, walk 3 m, walk back to the chair, and sit down. 48 hours
Secondary Visual analogue scale (VAS) at rest will be used to assess knee pain intensity 72 hours
Secondary Visual analogue scale (VAS) at movement will be used to assess knee pain intensity 72 hours
Secondary Time to first analgesic request the first time the patient ask for analgesia 72 hours
Secondary Total analgesic consumption Total consumption of postoperative rescue analgesics (total of paracetamol doses) will be recorded 72 hours
See also
  Status Clinical Trial Phase
Terminated NCT04040985 - Legion Primary Safety and Efficacy N/A
Recruiting NCT05279092 - Yale Steroid Enhanced Versus Exparel Nerveblock TKA RCT Study Phase 2
Completed NCT03286543 - Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System N/A
Not yet recruiting NCT04594447 - Physica System KR vs Physica System CR (K-20) N/A
Completed NCT02413996 - Effects of Virtual Reality Rehabilitation in Patients With Total Knee Arthroplasty N/A
Completed NCT01500252 - Patellar Resurfacing Versus Patellar Retention in Total Knee Arthroplasty - A Randomized Clinical Trial Phase 4
Completed NCT04081493 - The Efficacy of Low-load Blood Flow Restricted Resistance Before TKR N/A
Active, not recruiting NCT03339557 - Comparison of Three Knee Replacements N/A
Enrolling by invitation NCT04513145 - Adductor Canal Block Phase 2/Phase 3
Completed NCT06045078 - Aromatherapy in Total Knee Replacement N/A
Completed NCT02468934 - Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty (TKA) Using the SPRINT System N/A
Completed NCT02914210 - Virtual vs. Traditional Physical Therapy Following Total Knee Replacement N/A
Withdrawn NCT01523418 - Study to Observe Safety of Xarelto in VTE Prophlylaxis After Elective TKR (Total Knee Replacement) or THR (Total Hip Replacement) N/A
Completed NCT00795223 - Comparative Pain Control Between 0.2 or 0.3 Spinal Morphine and 0.25 or 0.5 % Bupivacaine for FNB After TKA Phase 4
Completed NCT01307202 - Morphine Consumption in Joint Replacement Patients, With or Without Gabapentin Treatment N/A
Completed NCT01522781 - 10 Year Outcome of Total Knee Replacement (TKR) Using Sigma Prosthesis N/A
Completed NCT01515449 - Predictors of Poor Outcomes in 1038 Sigma Knees N/A
Completed NCT04166539 - Neurotoxicity and Cardiotoxicity in Total Joint Arthroplasty
Completed NCT03454256 - Virtual Reality Rehabilitation in Patients With Total Knee Replacement N/A
Enrolling by invitation NCT06118073 - Effect of Mindfulness on Pain After Total Knee Arthroplasty N/A